MEDVASC – LDL : LOWER is BETTER !
Blog du Dr Jean-Pierre LAROCHE, médecin vasculaire sans filtre et pragmatique qui parle de Médecine Vasculaire et de l’actualité
Related Articles
Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF: The SUMMIT Trial
AbstractBackgroundThe SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide 1 receptor agonist tirzepatide decreased the risk of c…
Adriana Valenti Sabouret a Villa Mosca
Mercoledì 24 luglio, alle ore 21 nel giardino di Villa Mosca ad Alghero la scrittrice italo francese Adriana Valenti Sabouret presenta il libro, “Le nobili…
New insights into the therapeutic options to lower lipoprotein(a)
Elevated levels of lipoprotein(a) [Lp(a)] represent a risk factor for atherosclerotic cardiovascular diseases and are today considered an appealing pharmacological target over and above the…
Perspectives on early health economic evaluations of RNA… : Current Opinion in Endocrinology, Diabetes and Obesity
ial information on effectiveness for economic evaluations. We reviewed a recent early economic evaluation of RNA therapies targeted at Lp(a). Recent findings RNA-based therapies, if…
Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review – PubMed
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle that plays a causal role in atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, and calcific aortic valve stenosis.…
Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review – PubMed
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle that plays a causal role in atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, and calcific aortic valve stenosis.…
The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk
Background/Objectives: Hypercholesterolemia, accompanied by vascular inflammation, leads to the premature initiation and progression of atherosclerosis, and both are considered nowadays as well-established cardiovascular (CV) risk…
PCSK9-Targeting Drugs and Gender: Are There Any Differences?
Background: Atherosclerotic cardiovascular disease (ASCVD) is often perceived as a male-dominant condition, yet recent European data show that more women live with and die from…
Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
GLP-1R agonists may reduce cardiometabolic complications in part through reduction of inflammation. Here we show, using pharmacology and genetics, that the anti-inflammatory actions of GLP-1RAs…
Triple Assessments of Atherosclerosis in Patients With Heterozygous Familial Hypercholesterolemia:
AbstractBackgroundData on the appropriate timing and impact of atherosclerosis assessment in patients with heterozygous familial hypercholesterolemia (HeFH) are limited.ObjectivesThe authors aimed …